Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.077
Neutral
RSI(14)
39.399
Neutral
STOCH(KDJ)(9,3,3)
42.115
Neutral
ATR(14)
1.111
Low Volatility
CCI(14)
-43.670
Neutral
Williams %R
78.599
Sell
TRIX(12,20)
-0.509
Sell
StochRSI(14)
36.000
Sell
Search
IDEAYA Biosciences Inc
IDYAAdd to Watchlist
28.210USD
-0.630-2.18%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
2.48BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of IDEAYA Biosciences Inc
Currency: USD Updated: 2026-05-15Key Insights
IDEAYA Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 41 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.44.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
IDEAYA Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
IDEAYA Biosciences Inc Highlights
StrengthsRisks
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 835.26% year-on-year.
Fairly Valued
The company’s latest PE is -17.87, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 97.55M shares, decreasing 11.71% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.74K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.11.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
51.438
Target Price
+78.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of IDEAYA Biosciences Inc is 6.42, ranking 243 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
8.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.85
Operational Efficiency
2.72
Growth Potential
5.64
Shareholder Returns
7.11
IDEAYA Biosciences Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of IDEAYA Biosciences Inc is 6.47, ranking 261 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -17.87, which is -77.77% below the recent high of -3.97 and -52.81% above the recent low of -27.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 41/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of IDEAYA Biosciences Inc is 8.53, ranking 106 out of 382 in the Biotechnology & Medical Research industry. The average price target is 46.00, with a high of 79.00 and a low of 31.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
51.438
Target Price
+78.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
IDEAYA Biosciences Inc
IDYA
19
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of IDEAYA Biosciences Inc is 6.65, ranking 196 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 32.28 and the support level at 25.90, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
28.440
Sell
MA10
28.520
Sell
MA20
29.380
Sell
MA50
31.277
Sell
MA100
32.644
Sell
MA200
30.646
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of IDEAYA Biosciences Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 111.03%, representing a quarter-over-quarter increase of 0.37%. The largest institutional shareholder is Steven Cohen, holding a total of 1.84M shares, representing 2.10% of shares outstanding, with 1212.13% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of IDEAYA Biosciences Inc is 6.75, ranking 20 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.05. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-0.06
VaR
+4.98%
240-Day Maximum Drawdown
+25.91%
240-Day Volatility
+55.66%
Return
Best Daily Return
60 days
+7.61%
120 days
+7.61%
5 years
+35.70%
Worst Daily Return
60 days
-5.27%
120 days
-5.27%
5 years
-34.82%
Sharpe Ratio
60 days
-0.58
120 days
-0.54
5 years
+0.34
Risk Assessment
Maximum Drawdown
240 days
+25.91%
3 years
+69.23%
5 years
+69.42%
Return-to-Drawdown Ratio
240 days
+1.27
3 years
+0.11
5 years
+0.06
Skewness
240 days
+0.09
3 years
+0.20
5 years
+0.59
Volatility
Realised Volatility
240 days
+55.66%
5 years
+62.67%
Standardised True Range
240 days
+4.94%
5 years
+4.46%
Downside Risk-Adjusted Return
120 days
-103.25%
240 days
-103.25%
Maximum Daily Upside Volatility
60 days
+56.66%
Maximum Daily Downside Volatility
60 days
+34.23%
Liquidity
Average Turnover Rate
60 days
+1.36%
120 days
+1.20%
5 years
--
Turnover Deviation
20 days
-12.75%
60 days
+10.10%
120 days
-2.76%
Peer Comparison
Biotechnology & Medical Research
IDEAYA Biosciences Inc
IDYA
7.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
